These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 752868)

  • 21. Adjuvant chemoimmunotherapy of head and neck cancer.
    Taylor SG; Sisson GA; Bytell DE
    Recent Results Cancer Res; 1978; 68():297-308. PubMed ID: 313586
    [No Abstract]   [Full Text] [Related]  

  • 22. [Superficial bladder tumors. Preliminary results of a prospective study comparing endovesical BCG, adriamycin and thio-tepa].
    Martínez-Piñeiro JA; de la Peña J; Hidalgo L; Cisneros J; Jiménez León J; Machuca J; Perdices C
    Arch Esp Urol; 1985; 38(6):545-53. PubMed ID: 3938633
    [No Abstract]   [Full Text] [Related]  

  • 23. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
    Lamm DL; Thor DE; Harris SC; Reyna JA; Stogdill VD; Radwin HM
    J Urol; 1980 Jul; 124(1):38-40. PubMed ID: 6997513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell rosette test in squamous cell carcinoma of the head and neck.
    Eastham RJ; Mason JM; Jennings BR; Belew PW; Maguda TA
    Arch Otolaryngol; 1976 Mar; 102(3):171-5. PubMed ID: 1083730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.
    Hudson MA; Ratliff TL; Gillen DP; Haaff EO; Dresner SM; Catalona WJ
    J Urol; 1987 Aug; 138(2):295-8. PubMed ID: 3298694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCG treatment of periocular sarcoid.
    Lavach JD; Sullins KE; Roberts SM; Severin GA; Wheeler C; Lueker DC
    Equine Vet J; 1985 Nov; 17(6):445-8. PubMed ID: 4076159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract]   [Full Text] [Related]  

  • 28. BCG immune activation reduces growth and angiogenesis in an in vitro model of head and neck squamous cell carcinoma.
    Sánchez-Rodríguez C; Cruces KP; Riestra Ayora J; Martín-Sanz E; Sanz-Fernández R
    Vaccine; 2017 Nov; 35(47):6395-6403. PubMed ID: 29029943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nonspecific immunotherapy with BCG vaccine in bladder tumors].
    Damianov Kh; Patrashkov T; Petkov Ts; Tonchev T; Petrov P
    Khirurgiia (Sofiia); 1990; 43(1):48-53. PubMed ID: 2395285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled trial of methotrexate and Bacillus Calmette-Guérin therapy for advanced head and neck cancer.
    Papac R; Minor DR; Rudnick S; Solomon LR; Capizzi RL
    Cancer Res; 1978 Oct; 38(10):3150-3. PubMed ID: 356962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post treatment imaging in head and neck tumours.
    Chong VF
    Eur J Radiol; 2002 Nov; 44(2):81. PubMed ID: 12413676
    [No Abstract]   [Full Text] [Related]  

  • 33. Divergent effect of adjuvant chemo-immunotherapy on recurrence rates in node-negative and node-positive breast cancer patients.
    Jungi WF; Senn HJ; Amgwerd R; Hochuli E
    Eur J Cancer (1965); 1980; Suppl 1():169-72. PubMed ID: 7032928
    [No Abstract]   [Full Text] [Related]  

  • 34. Integration of chemotherapy into a combined modality treatment plan for head and neck cancer: a review.
    Glick JH; Taylor SG
    Int J Radiat Oncol Biol Phys; 1981 Feb; 7(2):229-42. PubMed ID: 6163756
    [No Abstract]   [Full Text] [Related]  

  • 35. Evaluation of immunocompetence in cancer patients.
    Hersh EM
    Laryngoscope; 1978 Jan; 88(1 Pt 2 Suppl 8):19-20. PubMed ID: 619201
    [No Abstract]   [Full Text] [Related]  

  • 36. Immunotherapy in patients with oral malignant disease.
    Perlin E
    Otolaryngol Clin North Am; 1979 Feb; 12(1):195-9. PubMed ID: 440739
    [No Abstract]   [Full Text] [Related]  

  • 37. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.
    Badalament RA; Herr HW; Wong GY; Gnecco C; Pinsky CM; Whitmore WF; Fair WR; Oettgen HF
    J Clin Oncol; 1987 Mar; 5(3):441-9. PubMed ID: 3546618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The immunotherapy of bladder tumors and the immunoprophylaxis of disease recurrence].
    Korovin AI; Savvin VT
    Urol Nefrol (Mosk); 1996; (1):19-21. PubMed ID: 8659034
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience with intravesical bacillus Calmette-Guèrin therapy of superficial bladder tumors.
    Herr HW; Pinsky CM; Whitmore WF; Sogani PG; Oettgen HF; Melamed MR
    Urology; 1985 Feb; 25(2):119-23. PubMed ID: 3881870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.